Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.33 |
| ▸ | SMURF2 | Q9HAU4 | 1/20 | 0.32 |
| ▸ | SMURF1 | Q9HCE7 | 1/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6728474 | 0.90 | IDH1 (0.32) | SMURF2SMURF1STING1PIK3CA | |
| SCHEMBL6727298 | 0.85 | P2RX3 (0.32) | P2RX7P2RX3P2RX2 | |
| SCHEMBL3032975 | 0.81 | MAOA (0.38) | — | |
| SCHEMBL6272108 | 0.75 | MAOA (0.47) | — | |
| SCHEMBL6272099 | 0.75 | MAOA (0.47) | — | |
| SCHEMBL6725878 | 0.74 | IDH1 (0.32) | — | |
| SCHEMBL6726498 | 0.73 | P2RX7 (0.32) | P2RX7P2RX3P2RX2 | |
| SCHEMBL3048209 | 0.72 | MAOA (0.35) | — | |
| SCHEMBL3035512 | 0.72 | MAOA (0.38) | PIK3CA | |
| SCHEMBL6493013 | 0.72 | MAOA (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | P2RX7 1463/4885SMURF2 4804/4885SMURF1 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.